Lung cancer drug 'could be good news for expatriate medical insurance customers' - Sign up to our mailing list
best live chat
Quick Quote
  • (inc. country & area code)
  • Please note this service is only available during London office hours. If your call is urgent we will endeavour to get back to you at the earliest possible opportunity.
  • This field is for validation purposes and should be left unchanged.

Lung cancer drug 'could be good news for expatriate medical insurance customers'

A lung cancer drug currently in development may be able to play a part in reducing expat insurance costs in the future.

Cancer charities have welcomed news the initial tests of drug PD173074 on mice have been a success.

Scientists from Imperial College London found the treatment to be more effective in treating small cell tumours than chemotherapy, offering a potential cure for a usually-fatal form of the disease.

Dr Rosemary Gillespie, chief executive of the Roy Castle Lung Cancer Foundation, said while she recognised the treatment is still some way off general availability, "the drugs that join production and development today are going to be the treatments of tomorrow".

Following the success of the initial animal-testing phase, the researchers now plan to take the drug into clinical trials.

According to data from healthcare charity Cancer Research, lung cancer is the second most common variety of the disease, with only seven per cent of patients surviving for more than five years after diagnosis.

Expatriate Healthcare specialise in providing international health insurance. Make sure you’re protected.

ADNFCR-1788-ID-19459438-ADNFCR

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Email this to someone
South AmericaNorth AmericaAfricaAustralia & New ZealandAsiaEurope